Latest Conference Articles

It’s been unclear whether statins affect the development of diabetic microvascular complications, therefore, Alam Park, MD, from the Ajou University School of Medicine in Korea, and colleagues set out to uncover just that.

Suleyman Kaynak, MD, and colleagues from the Dokuz Eylul University in Turkey, evaluated an alternative therapy for patients who do not respond well to intravitreal ranibizumab.

As new treatments and procedures are developed in the field of retinal medicine the American Society of Retina Specialists is launching its own journal to help its members and others in the field advance patient care.

For those doctors who go through the extended training to be certified retina specialists there is a wealth of knowledge to learn in order to provide the best care for patients.

An analysis presented at the 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS 2016) in San Francisco, California looked at “real world” outcomes with anti-vascular endothelial growth factor (VEGF) drugs to treat wet age-related macular degeneration (AMD).

Baruch Kuppermann, MD, PhD, and colleagues looked at gene expression modifications in retinal Müller cells treated with anti-VEGFs at the 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS 2016) in San Francisco, California.

David Eichenbaum, MD, an ophthalmologist from Florida, presented data from the HARBOR study at the 34th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS 2016) in San Francisco, California.

Research in the medical field covers a wide range of conditions and ways to not only treat them but also prevent them. Research is being done on a new vaccine for hepatitis B which has shown to be effective in patients with diabetes.

When people think of social networks their immediate reaction may be to think of web based networks and programs. A new recent study looked at the impact of having people to turn to for patients in the early stages of diabetes treatment and beyond.

While it is not yet approved for the treatment of patients with type 1 diabetes recent studies on canagliflozin have shown it could be an option for this patient population.

There are many factors and comorbidities to consider when treating diabetes. Finding the balance of treatment through medications can determine the quality of life of patients as they navigate through the condition.

With more than 60 presentations at the American Diabetes Association's meeting AstraZeneca showed a wide range of studies all geared towards helping patients with this condition.

Adding liraglutide to insulin treatment for type 1 diabetes has proven to lower body weight and reduce the frequency of hypoglycemia. Potential heart risks, however, have yet to be established.

When patients enter the hospital monitoring their blood glucose can be even more important to limit the effects of hypoglycemia. If the condition does develop it can make the stays longer and more expensive for everyone involved.

Blood glucose monitoring is an important part of patient care no matter where it is done, but it can be particularly important in hospital settings.

The field of diabetes care is continually moving forward. Even as data was being presented at this year's meeting of the American Diabetes Association the future was at the forefront of many people's minds in an effort to help these patients even more.

Even as gastric bypass continues to be a proven surgical option in the fight against the obesity epidemic work still remains to find a therapeutic option for this patient population as well.

There is no question that hunger can affect a person's life, a recent study looked at the scientific aspect of this discussion and what doctors can do to help patients with this challenge.

Especially for children with diagnosed with type 1 diabetes their journey with the condition will last decades affecting not only themselves but those around them. This is also true for patients with type 2 diabetes and how they confront these challenges can affect their life outside of diabetes as well.

Patients with type 2 diabetes are especially at risk for getting the hepatitis B infection, and a new vaccine proved to work better than the current one during a phase III trial.

“Early diabetic kidney disease (DKD), including increased albumin excretion and renal hyperfiltration (HF), is common in youth with type 2 diabetes,†a collaborative team of researchers began in a poster session at the American Diabetes Association (ADA 2016) 76th Scientific Sessions in New Orleans, Louisiana.

IBM Watson Health is working on several projects of their own as well as with partners in the field to move the treatment of diabetes forward in an effort to hep as many patients as possible.

At the recent ASCO conference in Chicago it was announced that Watson Health would be used to help with cancer treatment. A similar announcement was made at the American Diabetes Association's annual meeting in New Orleans.

As the treatment of diabetes becomes more complicated with a multitude of options on the market a long time member of the medical technology community is taking a big step to help fight this epidemic.

Everyone needs an adequate amount of sleep every night, but it should especially be a priority in pregnant women. However, there is a fine line between too much and too little sleep, but either way, both sides of the spectrum have an increase risk in gestational diabetes.

The obesity epidemic continues to grow in this country leaving the medical community to find new ways to help this patient population.

Maternal health just got that much more important as new research finds obesity contributes to chronic kidney disease risk in children.

Many healthcare providers have been pushing for the approval of insulin degludec/liraglutide (IDegLira) and the latest safety and efficacy results could help finally do that.

Not much is known about the relationship between oral contraceptives use and diabetes, but this untapped area got the spotlight during a session at the American Diabetes Association (ADA 2016) 76th Scientific Sessions in New Orleans, Louisiana.

Patients with type 1 diabetes can safely lower their blood glucose levels and hypoglycemia in a home setting with the dual hormone (glucagon and insulin) bionic pancreas, a new study revealed at the American Diabetes Association (ADA 2016) 76th Scientific Sessions in New Orleans, Louisiana.